Sep 2026 (Q3 FY26) — Oct 29, 2026
Supernus Pharmaceuticals Q3 FY26 — Record Revenue and Transformative Merger on Verge of Close
Read the full callSupernus Pharmaceuticals earnings: last reported Thu, 29 Oct 2026, for the quarter ended Sep 2026.
Price & Snapshot
1Y: $53.17 on 28 Oct 2025 → $41.84. High $57 (4 Nov 2025), low $37.88 (16 Oct 2026).
Reported
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 227 | +18.0% YoY | Quarterly, as filed | Quarter to Sep 2026 | Revenue from operations as filed. |
| Operating margin | 9.3 | +40.7 pts YoY | Operating profit / revenue | Quarter to Sep 2026 | For the quarter; a change is in percentage points. |
| Net profit | 20.9 | Quarterly, as filed | Quarter to Sep 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Supply chain
Named counterparties and similar headwinds disclosed on earnings calls.
channel destocking · Calendar Q3 2026
Beta Bionics, Inc. (BBNX) reported: Distributor Inventory Destocking Contributed to 178 bps sequential gross margin decline to 57.3%
Bausch Health Companies Inc. (BHC) reported: Xifaxan channel inventory normalization At least 300 bps drag on Q4 revenue growth and 500 bps drag on Q4 adjusted EBITDA growth
COOPER COMPANIES, INC. (COO) reported: U.S. channel inventory reduction impacting CooperVision revenue Caused Q3 CVI revenue to be flat; expected to cause Q4 CVI organic growth to be -2% to flat. Americas would have grown ~5% in Q3 without it.
demand conditions · Calendar Q3 2026
Avantor, Inc. (AVTR) reported: Macroeconomic and funding weakness in Europe Europe lagging Americas and Asia due to high energy costs and public budget constraints
Bausch Health Companies Inc. (BHC) reported: Macroeconomic softness and local competition in China aesthetics Contributed to a 4% organic revenue decline in Solta in Q3
weather or labor disruption · Calendar Q3 2026
CENTENE CORP (CNC) reported: Marketplace program integrity, IDR dispute abuse and CMS unauthorized-enrollment actions Reserve strengthening absorbed in Q3 (amount not disclosed); membership ~3.2M at year-end with continued attrition
QUEST DIAGNOSTICS INC (DGX) reported: Wage Increases 3% to 4% annual pressure (offset by Invigorate program).
UNIVERSAL HEALTH SERVICES INC (UHS) reported: Public Health Insurance Exchange Attrition 17% volume drop in Q3 FY26 (~$25M drag in Q3; minimum $15M incremental headwind in 2027)
freight and shipping · Calendar Q3 2026
ALIGN TECHNOLOGY INC (ALGN) reported: Freight Costs and Aligner Realized Price Compression Clear Aligner ASP declined 2.3% YoY to $1,215; gross margin missed internal outlook of 71% at 70.4%
Avantor, Inc. (AVTR) reported: Input cost inflation and geopolitical disruption Ongoing inflation across freight and materials, exacerbated by Middle East conflict
supply chain disruption · Calendar Q3 2026
AGILENT TECHNOLOGIES, INC. (A) reported: Rising material costs and supply chain headwinds null
Butterfly Network, Inc. (BFLY) reported: Geopolitical conflict and global supply chain bottlenecks Minor impacts to date; tariffs and AI-driven semiconductor component shortages monitored
GE HealthCare Technologies Inc. (GEHC) reported: Component and supply chain inflation Negative impact to Q3 gross and EBIT margins from memory chip costs and higher oil prices across logistics
Live Summary
Supernus Pharmaceuticals Q3 FY26 — Record Revenue and Transformative Merger on Verge of Close
Overview
Call summaries
Supernus Pharmaceuticals Q3 FY26 — Record Revenue and Transformative Merger on Verge of Close
Read the full callEvery analysed call
Financials
Net profit, year on year: +146% (quarter to sep 2026 against sep 2025).
| Line item | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 174 | 150 | 165 | 192 | 212 | 208 | 219 | 227 |
| Expenses | 153 | 160 | 153 | 252 | 216 | 216 | 277 | 206 |
| Operating profit | 21 | -10 | 12 | -60 | -4 | -8 | -58 | 21 |
| Operating margin | 12.3% | −6.8% | 7.3% | −31.4% | −1.9% | −4.0% | −26.5% | 9.3% |
| Other income | 5 | 4 | 5 | 2 | 2 | 2 | 0 | 2 |
| Interest | 0 | — | 0 | 0 | — | — | 2 | 1 |
| Profit before tax | 26 | -6 | 17 | -58 | -2 | -6 | -58 | 23 |
| Tax rate | 41.9% | −102.8% | −35.0% | 22.1% | −114.5% | 61.5% | −1.3% | 7.9% |
| Net profit | 15 | -12 | 22 | -45 | -4 | -2 | -58 | 21 |
| EPS ($ per share) | — | -0.21 | 0.40 | -0.80 | — | -0.04 | -1.01 | 0.36 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | 86 | 200 | 326 | 380 | 481 | 483 | 556 | 518 |
| Total liabilities | 525 | 565 | 759 | 873 | 816 | 356 | 332 | 391 |
| Fixed assets | 4 | 17 | 38 | 17 | 15 | 14 | 12 | 11 |
| Investments | 164 | 166 | 134 | 136 | 368 | — | — | — |
| Total assets | 978 | 1,160 | 1,504 | 1,689 | 1,703 | 1,278 | 1,368 | 1,453 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 129 | 143 | 138 | 127 | 117 | 111 | 172 | 47 |
| Cash from investing | -413 | -158 | -35 | -82 | -217 | 269 | -190 | 4 |
| Cash from financing | 376 | 4 | 4 | -130 | -10 | -398 | 12 | 9 |
| Net cash flow | 92 | -11 | 107 | -85 | -110 | -18 | -6 | 61 |
| Capital expenditure | -1 | -3 | -3 | — | -0 | -1 | -1 | -1 |
| Free cash flow | 128 | 140 | 135 | — | 116 | 111 | 171 | 46 |
98 filings between Nov 21, 2025 and Aug 12, 2026.
Purchases
None
No insider bought shares.
Sales
$10.26M
20 sales by 7 insiders
65% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Also filed: 2 other filings.
| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Bhatt Padmanabh P. | — | $5.42M | Mar 18, 2026 |
| Khattar Jack A. | — | $1.76M | Mar 13, 2026 |
| Mottola Frank | — | $1.10M | Mar 9, 2026 |
| GEMAYEL GEORGES | — | $1.00M | Mar 6, 2026 |
| Horich William Todd | — | $483.8K | Mar 10, 2026 |
| Hudson Frederick M. | — | $271.7K | Mar 12, 2026 |
| Sensenig Bethany | — | $228.3K | Feb 19, 2026 |
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 12, 2026 | Khattar Jack A. President, CEO | Tax withheld | 12,642 | $588.7K |
| Aug 12, 2026 | Khattar Jack A. President, CEO | Option exercise | 29,849 | $0 |
| Aug 12, 2026 | Mottola Frank SVP, Chief Tech. Ops. Officer | Option exercise | 1,650 | $0 |
| Aug 12, 2026 | DEC TIMOTHY C Senior Vice-President & CFO | Tax withheld | 604 | $28.1K |
| Aug 12, 2026 | Rubin Jonathan SVP, Chief Medical Officer | Tax withheld | 363 | $16.9K |
| Aug 12, 2026 | Bhatt Padmanabh P. Sr. VP of IP, CSO | Tax withheld | 1,158 | $53.9K |
| Aug 12, 2026 | Mottola Frank SVP, Chief Tech. Ops. Officer | Tax withheld | 797 | $37.1K |
| Aug 12, 2026 | Bhatt Padmanabh P. Sr. VP of IP, CSO | Option exercise | 2,500 | $0 |
| Aug 12, 2026 | Rubin Jonathan SVP, Chief Medical Officer | Option exercise | 750 | $0 |
| Aug 12, 2026 | DEC TIMOTHY C Senior Vice-President & CFO | Option exercise | 1,250 | $0 |
| Mar 18, 2026 | Bhatt Padmanabh P. Sr. VP of IP, CSO | Sale 10b5-1 plan | 412 | $20.8K |
| Mar 18, 2026 | Bhatt Padmanabh P. Sr. VP of IP, CSO | Option exercise 10b5-1 plan | 7,250 | $285.6K |
| Mar 18, 2026 | Bhatt Padmanabh P. Sr. VP of IP, CSO | Sale 10b5-1 plan | 6,838 | $338.8K |
| Mar 17, 2026 | Bhatt Padmanabh P. Sr. VP of IP, CSO | Sale 10b5-1 plan | 22,290 | $1.13M |
| Mar 17, 2026 | Bhatt Padmanabh P. Sr. VP of IP, CSO | Sale 10b5-1 plan | 27,710 | $1.38M |
| Mar 17, 2026 | Bhatt Padmanabh P. Sr. VP of IP, CSO | Option exercise 10b5-1 plan | 15,000 | $579.0K |
| Mar 17, 2026 | Bhatt Padmanabh P. Sr. VP of IP, CSO | Option exercise 10b5-1 plan | 12,250 | $450.2K |
| Mar 17, 2026 | Bhatt Padmanabh P. Sr. VP of IP, CSO | Option exercise 10b5-1 plan | 22,750 | $896.4K |
| Mar 16, 2026 | Bhatt Padmanabh P. Sr. VP of IP, CSO | Option exercise 10b5-1 plan | 4,250 | $125.8K |
| Mar 16, 2026 | Bhatt Padmanabh P. Sr. VP of IP, CSO | Option exercise 10b5-1 plan | 18,000 | $579.6K |
| Mar 16, 2026 | Bhatt Padmanabh P. Sr. VP of IP, CSO | Option exercise 10b5-1 plan | 5,000 | $139.7K |
| Mar 16, 2026 | Bhatt Padmanabh P. Sr. VP of IP, CSO | Option exercise 10b5-1 plan | 22,750 | $836.1K |
| Mar 16, 2026 | Bhatt Padmanabh P. Sr. VP of IP, CSO | Sale 10b5-1 plan | 34,114 | $1.71M |
| Mar 16, 2026 | Bhatt Padmanabh P. Sr. VP of IP, CSO | Sale 10b5-1 plan | 15,886 | $802.1K |
| Mar 13, 2026 | Khattar Jack A. President, CEO | Sale 10b5-1 plan | 24,138 | $1.21M |
| Mar 13, 2026 | Khattar Jack A. President, CEO | Sale 10b5-1 plan | 10,742 | $547.8K |
| Mar 13, 2026 | Khattar Jack A. President, CEO | Other 10b5-1 plan | 12,500 | — |
| Mar 13, 2026 | Khattar Jack A. President, CEO | Other 10b5-1 plan | 12,500 | — |
| Mar 13, 2026 | Khattar Jack A. President, CEO | Sale 10b5-1 plan | 120 | $6.2K |
| Mar 12, 2026 | Hudson Frederick M. Director | Sale | 5,369 | $271.7K |
| Mar 10, 2026 | Horich William Todd SVP, Commercial Operations | Sale | 4,439 | $244.1K |
| Mar 9, 2026 | Horich William Todd SVP, Commercial Operations | Sale | 4,438 | $239.7K |
| Mar 9, 2026 | Mottola Frank SVP, Chief Tech. Ops. Officer | Sale | 1,623 | $87.1K |
| Mar 6, 2026 | DEC TIMOTHY C Senior Vice-President & CFO | Option exercise | 3,000 | $0 |
| Mar 6, 2026 | Horich William Todd SVP, Commercial Operations | Tax withheld | 521 | $28.5K |
| Mar 6, 2026 | Horich William Todd SVP, Commercial Operations | Option exercise | 1,125 | $0 |
| Mar 6, 2026 | Horich William Todd SVP, Commercial Operations | Option exercise | 3,750 | $0 |
| Mar 6, 2026 | Horich William Todd SVP, Commercial Operations | Tax withheld | 1,216 | $66.6K |
| Mar 6, 2026 | Horich William Todd SVP, Commercial Operations | Option exercise | 2,625 | $0 |
| Mar 6, 2026 | Mottola Frank SVP, Chief Tech. Ops. Officer | Tax withheld | 1,793 | $98.1K |
| Mar 6, 2026 | Mottola Frank SVP, Chief Tech. Ops. Officer | Option exercise | 3,750 | $0 |
| Mar 6, 2026 | Horich William Todd SVP, Commercial Operations | Tax withheld | 1,718 | $94.0K |
| Mar 6, 2026 | Khattar Jack A. President, CEO | Tax withheld | 16,574 | $907.1K |
| Mar 6, 2026 | Khattar Jack A. President, CEO | Option exercise | 38,640 | $0 |
| Mar 6, 2026 | DEC TIMOTHY C Senior Vice-President & CFO | Tax withheld | 1,450 | $79.4K |
| Mar 6, 2026 | DEC TIMOTHY C Senior Vice-President & CFO | Option exercise | 3,000 | $0 |
| Mar 6, 2026 | DEC TIMOTHY C Senior Vice-President & CFO | Tax withheld | 1,433 | $78.4K |
| Mar 6, 2026 | GEMAYEL GEORGES Director | Sale | 8,787 | $465.7K |
| Mar 6, 2026 | GEMAYEL GEORGES Director | Option exercise | 7,905 | $200.0K |
| Mar 5, 2026 | GEMAYEL GEORGES Director | Sale | 10,000 | $537.1K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Free account. Everything above stays public.
Write why you follow SUPERNUS PHARMACEUTICALS, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading